FAB Pharma: Narrower is Better

FAB Pharma S.A.S. believes that by targeting a new mechanism of action in the fatty acid biosynthesis pathway, it can develop narrow-spectrum antibiotics against methicillin-resistant Staphylococcus aureus with a much better side effect profile than existing drugs.

FAB spun out of Mutabilis S.A. in July 2009 with lead compound Fab-001. The company was to announce on Monday that it started a Phase I trial of the antibiotic to treat MRSA infections and that it raised €2.3 million ($3.3 million) in a series A round co-led by Bioam Gestion and CDC Innovation...